Jani MS, Zou J, Veetil AT, & Krishnan Y. A DNA-based fluorescent probe maps NOS3 activity with subcellular spatial resolution. (2020) Nat Chem Biol 16:660–666. doi: 10.1038/s41589-020-0491-3
Objectives: Usage of novel fluorescent DNA-based probe technology to map activities of endogenous NOS3 in live cells provides a platform to discover selective regulators of NOS3 in PM and TGN.
Summary: Targeting of plasma membrane (PM) and trans-Golgi network (TGN) shows that NOS3 is tenfold less active at the Golgi but its activity is essential for the structural integrity of the Golgi.
Dose: Anti-No-L-Cysteine was used in immunofluorescence.
Mnaimneh S, Damaj M, Barhoumi R, Mouneimne Y, Geffard M, Veyret B, Vincendeau P (2004) Evidence for nitric oxide involvement in experimental autoimmune encephalomyelitis and adjuvant-induced arthritis in Lewis rat. The Pain Clinic 16(3):229-243.
Alencar JL, Lobysheva I, Chalupsky K, Geffard M, Nepveu F, Stoclet JC, Muller B (2003) S-nitrosating nitric oxide donors induce long-lasting inhibition of contraction in isolated arteries. J Pharmacol Exp Ther 307(1):152-159.
Alencar JL, Lobysheva I, Geffard M, Sarr M, Schott C, Schini-Kerth VB, Nepveu F, Stoclet JC, Muller B (2003) Role of S-nitrosation of cysteine residues in long-lasting inhibitory effect of nitric oxide on arterial tone. Mol Pharmacol 63(5):1148-1158..
Lorch SA, Foust R 3rd, Gow A, Arkovitz M, Salzman AL, Szabo C, Vayert B, Geffard M, Ischiropoulos H (2000) Immunohistochemical localization of protein 3-nitrotyrosine and S-nitrosocysteine in a murine model of inhaled nitric oxide therapy. Pediatr Res 47(6):798-805.
Mnaimneh S, Geffard M, Veyret B, Vincendeau P (1999) Detection of nitrosylated epitopes in Trypanosoma brucei gambiense by polyclonal and monoclonal anti-conjugated-NO-cysteine antibodies. C R Acad Sci III 322(4):311-322.
Mnaimneh S, Geffard M, Veyret B, Vincendeau P (1997) Albumin nitrosylated by activated macrophages possesses antiparasitic effects neutralized by anti-NO-acetylated-cysteine antibodies. J Immunol 158(1):308-314.